When cannabinoids like THC and CBD are swallowed, the liver destroys most of the dose before it ever reaches the bloodstream. A new formulation science review explores how absorbing cannabinoids through the cheek or under the tongue could dramatically improve how much medicine actually gets through, though none of these newer approaches have been validated in large clinical trials yet.

Clinicians who prescribe cannabinoid medicines routinely confront a frustrating pharmacokinetic reality: oral CBD and THC bioavailability hovers between 6 and 19 percent, meaning most of the administered dose never reaches its target. Inhaled delivery improves absorption but introduces pulmonary toxicity risks and dose unpredictability. The only approved oromucosal product, Sativex, has well-documented limitations including mucosal irritation and inadvertent swallowing. Understanding what formulation innovations are on the horizon is critical for any clinician advising patients on cannabinoid therapy, because better delivery platforms could fundamentally reshape dosing precision and therapeutic reliability.

Cannabinoids have demonstrated pharmacological activity across pain, spasticity, epilepsy, and nausea indications, yet their clinical utility is consistently undermined by poor bioavailability when administered orally. THC and CBD are both highly lipophilic, undergo extensive first-pass hepatic metabolism via cytochrome P450 enzymes, and degrade in the gastrointestinal tract. These factors produce systemic availability of roughly 6 to 10 percent for THC and 6 to 19 percent for CBD after oral ingestion, compared with approximately 31 percent via inhalation. Oral mucosal delivery, specifically through the buccal (cheek) and sublingual (under the tongue) routes, offers a mechanistically attractive alternative because these tissues are richly vascularized and drain directly into systemic circulation, largely bypassing hepatic first-pass metabolism.

This narrative review catalogues the formulation strategies most likely to exploit these anatomical advantages, including fast-dissolving sublingual films, mucoadhesive buccal matrices, in situ gels, lipid-based particulate carriers, and permeation enhancers such as terpenes. The authors highlight that buccal and sublingual tissues differ substantially in epithelial thickness and permeability, demanding distinct product design approaches. Advanced fabrication methods such as hot melt extrusion and 3D printing are discussed as routes toward personalized dosing. Importantly, the review generates no original experimental data and does not employ systematic search methods. All conclusions are literature-synthesis-level, and the authors acknowledge that clinical validation of these novel dosage forms remains an unmet need.

This review gets something fundamentally right that is often overlooked in cannabinoid conversations: the delivery method is not a trivial detail. It is, in many cases, the single largest variable determining whether a patient gets a therapeutic dose or essentially wastes their medicine. The formulation science described here is genuinely promising, and the physiological rationale for buccal and sublingual routes is sound. But I want to be honest about the distance between bench-side innovation and bedside reality. Nearly every formulation discussed here lacks rigorous human pharmacokinetic data, and the review itself does not include systematic search methods, so we cannot be certain the literature was surveyed comprehensively.

In my practice, I already counsel patients to use sublingual tinctures and hold them under the tongue for at least 60 to 90 seconds precisely because bypassing the liver makes a meaningful difference. I see patients who switched from edibles to sublingual administration and noticed improved consistency in their response. This review reinforces that clinical observation with mechanistic clarity, and it gives me confidence that the field is moving toward better products. But I am not ready to tell patients that any of the novel dosage forms described here are available or proven. We are watching the science develop, and that is worth tracking closely.

This review sits at an important inflection point in cannabinoid therapeutics. We have a growing number of approved and off-label cannabinoid indications, a single approved oromucosal product with known shortcomings, and a robust preclinical formulation pipeline that has not yet been pressure-tested through phase II or III trials. For clinicians, the practical value of this review lies in understanding why current delivery methods underperform and which emerging approaches have the strongest mechanistic basis. It does not, however, provide evidence that any specific novel formulation improves clinical outcomes over existing products.

Pharmacologically, clinicians should note that bypassing first-pass metabolism changes more than just bioavailability: it also alters the metabolite profile. THC metabolized hepatically produces 11-hydroxy-THC, which is psychoactive and may contribute to adverse effects at unpredictable levels. Mucosal absorption that avoids this pathway could, in theory, produce a more predictable psychoactive profile, though this has not been confirmed in controlled trials. Drug interaction considerations remain relevant, as CYP3A4 and CYP2C19 activity still

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care